Accelerating Clinical Trials in the EU (ACT EU)
Submitted by Anonymous (not verified) on 22 January 2025 - 13:06
Accelerating Clinical Trials in the EU (ACT EU)
Appendix 1: Acceptable intakes established for N-nitrosamines
Submitted by Anonymous (not verified) on 22 January 2025 - 13:04
Appendix 1: Acceptable intakes established for N-nitrosamines
Human medicines European public assessment report (EPAR): Inlyta, axitinib, Date of authorisation: 03/09/2012, Revision: 17, Status: Authorised
Submitted by Anonymous (not verified) on 22 January 2025 - 11:24
Human medicines European public assessment report (EPAR): Inlyta, axitinib, Date of authorisation: 03/09/2012, Revision: 17, Status: Authorised
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 25 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 25 February 2025, 11:00 (CET) to 25 February 20
Submitted by Anonymous (not verified) on 22 January 2025 - 10:53
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 25 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 25 February 2025, 11:00 (CET) to 25 February 2025, 11:45 (CET)
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 11 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 February 2025, 11:00 (CET) to 11 February 20
Submitted by Anonymous (not verified) on 22 January 2025 - 10:52
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 11 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 February 2025, 11:00 (CET) to 11 February 2025, 11:45 (CET)
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 4 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 February 2025, 11:00 (CET) to 4 February 2025,
Submitted by Anonymous (not verified) on 22 January 2025 - 10:50
Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 4 February 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 February 2025, 11:00 (CET) to 4 February 2025, 11:45 (CET)
Human medicines European public assessment report (EPAR): Thalidomide BMS (previously Thalidomide Celgene), thalidomide, Date of authorisation: 16/04/2008, Revision: 33, Status: Authorised
Submitted by Anonymous (not verified) on 22 January 2025 - 10:37
Human medicines European public assessment report (EPAR): Thalidomide BMS (previously Thalidomide Celgene), thalidomide, Date of authorisation: 16/04/2008, Revision: 33, Status: Authorised
Innovation Task Force (ITF) briefing meeting request form
Submitted by Anonymous (not verified) on 22 January 2025 - 10:00
Innovation Task Force (ITF) briefing meeting request form
Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, efavirenz,emtricitabine,tenofovir disoproxil, Date of authorisation: 08/02/2018, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 22 January 2025 - 10:00
Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, efavirenz,emtricitabine,tenofovir disoproxil, Date of authorisation: 08/02/2018, Revision: 13, Status: Authorised
Guideline on specific adverse reaction follow-up questionnaires (Specific AR FUQ)
Submitted by Anonymous (not verified) on 22 January 2025 - 9:23
Guideline on specific adverse reaction follow-up questionnaires (Specific AR FUQ)